Original Investigation December 21, 2021 Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al JAMA. 2021;326(23):2375-2384. doi:10.1001/jama.2021.21316 Abstract Importance  Proactive therapeutic drug monitoring (TDM...

ARTICLES|ONLINE FIRST Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, et al Lancet Published:December 15, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)02392-8 Summary Background Patients hospitalised with COVID-19 are at risk for thrombotic events after disch...

ARTICLES| VOLUME 399, ISSUE 10321, P237-248, JANUARY 15, 2022 Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Scott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al Lancet 2022; 399: 237-248 Summary Background ...

Original Investigation December 20, 2021 Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial Ting Li, Jun Li, Liyong Yuan, et al JAMA. Published online December 20, 2021. doi:10.1001/jama.2021.22647 Abstract Importance  In adults undergoing hip fracture surgery, regional anesthesia may reduce postoperative delirium, but there is ...

ARTICLES|ONLINE FIRST Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial Arabella S V Stuart, Robert H Shaw, Xinxue Liu, et al Lancet Published:December 06, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)02718-5 Summary Background Given the importance of flexible use of di...

ARTICLES| VOLUME 398, ISSUE 10318, P2258-2276, DECEMBER 18, 2021 Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Alasdair P S Munro, Leila Janani, Victoria Cornelius, et al Lancet 2021; 398: 2258-2276 Summary Background Few data exist on the comparative safety and immunogenicity of differen...

Original Investigation December 13, 2021 Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial Peter A. Dargaville, C. Omar F. Kamlin, Francesca Orsini, et al JAMA. Published online December 13, 2021. doi:10.1001/jama.2021.21892 Abstract Importance  The benefits of surfactant administrati...

Original Investigation Caring for the Critically Ill PatientDecember 8, 2021 Effect of Use of a Bougie vs Endotracheal Tube With Stylet on Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial Brian E. Driver, Matthew W. Semler, Wesley H. Self, et al JAMA. Published online December 8, 2021. doi:10.1001/jama.2021.22002 Abstract Importance  For critically i...

ORIGINAL ARTICLE Milvexian for the Prevention of Venous Thromboembolism Jeffrey I. Weitz, John Strony, Walter Ageno, et al N Engl J Med 2021; 385:2161-2172DOI: 10.1056/NEJMoa2113194 Abstract BACKGROUND Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an ...

ORIGINAL ARTICLE Protection against Covid-19 by BNT162b2 Booster across Age Groups Yinon M. Bar-On, Yair Goldberg, Micha Mandel, et al N Engl J Med 2021; 385:2421-2430DOI: 10.1056/NEJMoa2115926 Abstract BACKGROUND After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, the booster campaign in Israel was gradually expanded to persons in y...